Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 38963256.
- Also identified by DOI 10.1002/ana.27027 and PMC identifier 11324391.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.
Medical subject headings
- Amyloid beta-Peptides
- Multiple Sclerosis